Trials / Completed
CompletedNCT00034684
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Farnesyl Protein Transferase Inhibitor |
Timeline
- Start date
- 2001-07-01
- Primary completion
- 2003-10-01
- Completion
- 2003-10-01
- First posted
- 2002-05-02
- Last updated
- 2015-06-17
Source: ClinicalTrials.gov record NCT00034684. Inclusion in this directory is not an endorsement.